Cancer resistance to therapy occurs through a selection process generally thought to be driven by mutations. In a recent study, Hugo et al. use multidimensional analysis of the dynamic genetic, transcriptional, epigenetic, and immune landscape alterations in baseline and MAPK inhibitor-resistant melanoma tumors, demonstrating a role for ‘non-genomic’ drivers in cancer evolution.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados